Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

Antigen escape is an even more significant obstacle for CAR T-cell treatment of solid tumors, where antigen heterogeneity obstructs effective targeting of all tumor cells within a tumor, and ...

By Pooja Toshniwal Paharia New research reveals how common dietary proteins like bovine serum albumin (BSA) or ovalbumin (OVA ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

These CAR-T cells showed antigen-dependent activation, effectively killing GUCY2C-expressing cancer cells in vitro and providing long-term protection in mouse models against lung metastases of CRC. 39 ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 ...

Characterization of antigen-specific T cell responses typically is a critical constituent of these immunological investigations which can also aid in patient stratification for future trials. As a ...